Italia markets open in 8 hours 3 minutes

Bristol-Myers Squibb Company (BMY)

NYSE - Nasdaq Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
62,46-0,15 (-0,24%)
Alla chiusura: 04:00PM EST
62,49 +0,03 (+0,05%)
Dopo ore: 06:53PM EST

Bristol-Myers Squibb Company

430 East 29th Street
14th Floor
New York, NY 10016
United States
212 546 4000

SettoreDrug Manufacturers—General
Impiegati a tempo pieno30.250

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Giovanni Caforio M.D.Chairman & CEO6,69MN/D1965
Mr. David V. ElkinsExec. VP & CFO3,24MN/D1968
Ms. Sandra Leung Esq.Exec. VP & Gen. Counsel3,03MN/D1961
Dr. Christopher S. BoernerExec. VP & Chief Commercialization Officer2,78MN/D1971
Mr. Rupert Vessey M.A.Exec. VP and Pres of Research & Early Devel.3,24M1,46M1965
Mr. Paul von AutenriedExec. VP & Chief Information OfficerN/DN/D1962
Mr. Timothy PowerVP & Head of Investor RelationsN/DN/DN/D
Mr. Adam DubowSr. VP, Chief Compliance & Ethics OfficerN/DN/D1967
Ms. Ann M. Powell JudgeExec. VP & Chief HR OfficerN/DN/D1966
Mr. Louis S. SchmuklerExec. VP and Pres of Global Product Devel. & SupplyN/DN/D1956
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.


Bristol-Myers Squibb Company develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; Inspirna, Inc.; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Governance aziendale

L'ISS Governance QualityScore di Bristol-Myers Squibb Company al 26 settembre 2021 è 2. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 4; diritti degli azionisti: 3; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.